These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11474912)

  • 1. Irritable bowel syndrome: toward a cost-effective management approach.
    Martin R; Barron JJ; Zacker C
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S268-75. PubMed ID: 11474912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic consequences of irritable bowel syndrome: a US employer perspective.
    Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
    Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of care for irritable bowel syndrome patients in a health maintenance organization.
    Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD
    Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod treatment for IBS: a model of indirect costs.
    Smith DG; Barghout V; Kahler KH
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spectrum of irritable bowel syndrome: A clinical review.
    Gilkin RJ
    Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irritable bowel syndrome - an evidence-based approach to diagnosis.
    Cash BD; Chey WD
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1235-45. PubMed ID: 15191504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition and classification of irritable bowel syndrome: current consensus and controversies.
    Longstreth GF
    Gastroenterol Clin North Am; 2005 Jun; 34(2):173-87. PubMed ID: 15862928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis.
    Mein SM; Ladabaum U
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1199-210. PubMed ID: 15153173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost of migraine and its treatment.
    Goldberg LD
    Am J Manag Care; 2005 Jun; 11(2 Suppl):S62-7. PubMed ID: 16095269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.
    Creed F; Fernandes L; Guthrie E; Palmer S; Ratcliffe J; Read N; Rigby C; Thompson D; Tomenson B;
    Gastroenterology; 2003 Feb; 124(2):303-17. PubMed ID: 12557136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
    Brun-Strang C; Dapoigny M; Lafuma A; Wainsten JP; Fagnani F
    Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1097-103. PubMed ID: 17998835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of irritable bowel syndrome in Canada.
    Bentkover JD; Field C; Greene EM; Plourde V; Casciano JP
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():89A-96A. PubMed ID: 10202215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of office-based physician visits for irritable bowel syndrome and for migraine and asthma.
    Kozma CM; Barghout V; Slaton T; Frech F; Reeder CE
    Manag Care Interface; 2002 Sep; 15(9):40-3, 49. PubMed ID: 12244649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irritable bowel syndrome: a management strategy.
    Thompson WG
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):453-60. PubMed ID: 10580921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing irritable bowel syndrome.
    van Zanten SV
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S12-7. PubMed ID: 12775998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
    Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
    Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden attributable to functional bowel disorders in Iran: a cross-sectional population-based study.
    Moghimi-Dehkordi B; Vahedi M; Pourhoseingholi MA; Khoshkrood Mansoori B; Safaee A; Habibi M; Pourhoseingholi A; Zali MR
    J Dig Dis; 2011 Oct; 12(5):384-92. PubMed ID: 21955432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures.
    Camilleri M; Williams DE
    Pharmacoeconomics; 2000 Apr; 17(4):331-8. PubMed ID: 10947488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care utilization and economic issues in irritable bowel syndrome.
    Gralnek IM
    Eur J Surg Suppl; 1998; (583):73-6. PubMed ID: 10027677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.